{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:35:59Z","timestamp":1793140559124,"version":"4.5.0"},"publisher-location":"Chichester, UK","reference-count":41,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001447.pub2","type":"reference-entry","created":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T14:23:19Z","timestamp":1170771799000},"source":"Crossref","is-referenced-by-count":172,"title":["Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)"],"prefix":"10.1002","author":[{"given":"Robert G","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"key":"10.1002\/14651858.CD001447.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD001447.pub2-BIB3|cit3","unstructured":"Meininger V Lacomblez L Bensimon G Unpublished report: controlled trial of riluzole in patients with advanced ALS RP 54272-302 1995"},{"issue":"9013","key":"10.1002\/14651858.CD001447.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001447.pub2-BIB5|cit5","first-page":"851","article-title":"Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi"},{"key":"10.1002\/14651858.CD001447.pub2-BIB6|cit6","first-page":"33","article-title":"Open label study of riluzole for the treatment of amyotrophic lateral sclerosis","volume":"8","author":"Arriada-Mendicoa","year":"1999","journal-title":"Revista Ecuatoriana de Neurologia"},{"issue":"4","key":"10.1002\/14651858.CD001447.pub2-BIB7|cit7","first-page":"357","article-title":"Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS","volume":"156","author":"Couratier","year":"2000","journal-title":"Revue Neurologique"},{"issue":"1-2","key":"10.1002\/14651858.CD001447.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-510X(99)00225-7","article-title":"The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation","volume":"169","author":"Desiato","year":"1999","journal-title":"Journal of Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00702-004-0220-1","article-title":"High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study","volume":"112","author":"Graf","year":"2005","journal-title":"Journal of Neural Transmission"},{"issue":"8","key":"10.1002\/14651858.CD001447.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/00001756-199806010-00016","article-title":"Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy","volume":"9","author":"Kalra","year":"1998","journal-title":"Neuroreport"},{"key":"10.1002\/14651858.CD001447.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14660820500396984","article-title":"Audit of outcomes in motor neuron disease (MND) patients treated with riluzole","volume":"7","author":"Mitchell","year":"2006","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"1","key":"10.1002\/14651858.CD001447.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1529-8027.2000.00513-45.x","article-title":"An open study of riluzole versus riluzole plus gabapentin in amyotrophic lateral sclerosis","volume":"5","author":"Palma","year":"2000","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-2007-1017633","article-title":"Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)","volume":"26","author":"Pongratz","year":"1999","journal-title":"Aktuelle Neurologie"},{"issue":"4","key":"10.1002\/14651858.CD001447.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archneur.55.4.526","article-title":"An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole","volume":"55","author":"Riviere","year":"1998","journal-title":"Archives of Neurology"},{"issue":"9046","key":"10.1002\/14651858.CD001447.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)60977-4","article-title":"Effects of riluzole on symptom progression in amyotrophic lateral sclerosis","volume":"349","author":"Sojka","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD001447.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: a population based study in Southern Italy","volume":"14","author":"Zoccolella","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001447.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders"},{"key":"10.1002\/14651858.CD001447.pub2-BIB18|cit18","unstructured":"Booth-Clibborn N Best L Stein K Riluzole for motor neurone disease Southampton: Wessex Institute for Health Research & Development (DEC Report 73) 1997"},{"key":"10.1002\/14651858.CD001447.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(05)70326-4","article-title":"Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial","volume":"5","author":"Bourke","year":"2006","journal-title":"Lancet Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD001447.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","article-title":"El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases\/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial \"Clinical limits of amyotrophic lateral sclerosis\" workshop contributors","volume":"124","author":"Brooks","year":"1994","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001447.pub2-BIB21|cit21","first-page":"60","article-title":"Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - Motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study","volume":"2","author":"Brooks","year":"2001","journal-title":"ALS and other motor neuron diseases"},{"key":"10.1002\/14651858.CD001447.pub2-BIB22|cit22","unstructured":"Chilcott J Golightly P Jefferson D McCabe CJ Walters S The use of riluzole in the treatment of Amyotrophic Lateral Sclerosis (Motor Neurone Disease). Working Group on Acute Purchasing Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield 1997"},{"key":"10.1002\/14651858.CD001447.pub2-BIB23|cit23","unstructured":"Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR) Rilutek The European Agency for the Evaluation of Medicinal Products"},{"issue":"2","key":"10.1002\/14651858.CD001447.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5020","article-title":"The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review","volume":"5","author":"Stewart","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"9-10","key":"10.1002\/14651858.CD001447.pub2-BIB25|cit25","first-page":"185","article-title":"Riluzole and ALS therapy","volume":"146","author":"Hugon","year":"1996","journal-title":"Weiner Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD001447.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.47.6_Suppl_4.251S","article-title":"ALS therapy: targets for the future","volume":"47","author":"Hugon","year":"1996","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD001447.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1212\/WNL.39.12.1635","article-title":"A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis","volume":"39","author":"Lacomblez","year":"1989","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.46.5.1442","article-title":"Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS","volume":"46","author":"McGuire","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/BF03160577","article-title":"The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS\/Riluzole Study Group III","volume":"244","author":"Meininger","year":"1997","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001447.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD001447.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1212\/WNL.47.4_Suppl_2.86S","article-title":"Clinical trials of riluzole in patients with amyotrophic lateral sclerosis","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001447.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1212\/WNL.52.7.1311","article-title":"Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)","volume":"52","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/WNL.49.3.657","article-title":"Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole","volume":"49","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447.pub2-BIB34|cit34","unstructured":"National Institute for Clinical Excellence Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease Technology Appraisal Guidance 2001"},{"issue":"24","key":"10.1002\/14651858.CD001447.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001447.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0959-4388(96)80103-6","article-title":"Therapeutic horizons for amyotrophic lateral sclerosis","volume":"6","author":"Rothstein","year":"1996","journal-title":"Current Opinion in Neurobiology"},{"issue":"9","key":"10.1002\/14651858.CD001447.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJM199403033300911","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell?","volume":"330","author":"Rowland","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001447.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.50.1.66","article-title":"Prognostic indicators of survival in ALS","volume":"50","author":"Stambler","year":"1998","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447.pub2-BIB39|cit39","first-page":"43","article-title":"Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period (1999-2000)","volume":"2","author":"Traynor","year":"2001","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447.pub2-BIB40|cit40","first-page":"43","article-title":"The Kings' Database 1999-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis","volume":"2","author":"Turner","year":"2001","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"9030","key":"10.1002\/14651858.CD001447.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(96)03181-9","article-title":"Riluzole","volume":"348","author":"Wokke","year":"1996","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001447.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001447.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:03:04Z","timestamp":1628528584000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001447.pub2"}},"subtitle":[],"editor":[{"given":"Robert G","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001447.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001447.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2007,1,24]]}}}